The Abbott TDX fluorescence polarisation immunoassay method was used to measure plasma digoxin. The therapeutic range eight to 10 hours postdose is 1-2 to 2-4 nmol/l with this assay.
Results
Thirty two measurements of plasma digoxin were obtained in 25 patients (see Table) . All the patients were normokalaemic, though 20 were taking diuretics. Seven had renal impairment (creatinine 120-200 Mmol/l) but their digoxin doses varied Rapid plasma digoxin assay in outpatients-a useful routine technique? across the whole range seen in the study (62-5 Mg on alternate days to 375 pg daily) and none showed signs of digoxin toxicity. Knowledge of plasma creatinine and potassium concentrations did not indicate that the proposed maintenance dose should be altered. All patients in whom heart rate was thought to be less than optimally controlled (cases 1-6) were given an increased digoxin dose and the subsequent response was adequate. In no case did knowledge of the digoxin concentration lead to a change in the proposed management, even in case 3, in whom the initial concentration was in the therapeutic range.
In one of the 19 optimally controlled patients (case 8) the finding of a digoxin concentration of 0-32 nmol/l did alter management since despite a resting heart rate of 92/min on 125 pg daily the patient complained of mild palpitation; this was abolished when a daily dose of 250 pg was given and plasma digoxin was 0 95 nmol/l. Cases 3, 17, and 23 had concentrations just above the therapeutic range but all were well and remained so for at least another four weeks.
Discussion
Two centuries after Withering's report on digitalis' our small study further emphasises the importance of clinical observation in the use of digoxin. In only one patient in 25 (and one measurement in 32) did the knowledge of a plasma digoxin concentration influence management. Thus, in contrast to the situation with anticonvulsants, which have a similarly narrow therapeutic ratio and fickle reputation, we cannot advocate widespread adoption of a same visit outpatient service for routine digoxin assay for patients with atrial fibrillation attending follow up clinics such as ours.
Retrospective studies have suggested that while clinical judgement should remain the cornerstone of therapy with digoxin, knowledge of plasma concentrations may assist when toxicity is suspected, when atrial fibrillation is refractory to a reasonable dose of digoxin, and when renal function is impaired.6 In our study only five concentrations exceeded [1] [2] [3] [4] [5] nmol/l, so it is not surprising that plasma digoxin concentration was not a useful indicator of toxicity. Initially we were surprised to find that no patient showed clinical evidence of toxicity; in the early 1970s we would have expected to find that about 25% of patients had evidence of digoxin toxicity."6 A cautious dose selection policy was shown in the current study-42 of 68 similar patients described in 1970 were taking more than 375 pg a day, the maximum dose used in our study. 6 Although we might have expected to find a knowledge of digoxin concentrations useful in six patients who were "under-digitalised" at follow up, their management based on clinical information was satisfactory. Furthermore, four of seven patients with optimal heart rates but digoxin concentrations below 250 1 nmol/l had demonstrated benefit from digoxin. Cases 5, 6, and 8 had needed an increased dose of digoxin during the study and case 11 had a documented fast ventricular response rate before digoxin was started. Modest doses of digoxin may result in very low plasma digoxin concentrations but some patients will still respond adequately.
In view of our policy of cautious dose selection, it is not surprising to find that in our seven patients with moderate renal impairment no benefit was derived from a knowledge of plasma digoxin concentration despite the risk of toxicity.
We do not of course deny the potential value of the rapid assay in apparently refractory atrial fibrillation or in patients with evidence of toxicity or where there is the suspicion of poor compliance.
Our conclusion depends in part upon the current dose selection policy which is more conservative than that used 15 years ago; our data imply that this policy is reasonable provided physicians continue to apply their clinical senses with the diligence shown by Withering two centuries ago. 
